Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a U.S.-based biotechnology company focused on medicines for rare diseases, with commercial franchises in Fabry disease and late-onset Pompe disease. Its marketed products include Galafold® (migalastat), an oral therapy for Fabry patients with amenable genetic variants, and the two-component Pompe regimen Pombiliti® + Opfolda® (cipaglucosidase alfa-atga/miglustat). The company sells globally through specialty distributors and pharmacies, with reimbursement and government payors playing a central role in access and pricing. Amicus also expands its pipeline via partnering and licensing, including an exclusive U.S. commercialization license for Dimerix’s Phase 3 candidate DMX-200 for FSGS and other indications.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOral precision therapy for Fabry patients with amenable genetic variants, sold commercially across multiple countries.
Two-component therapy for adults with late-onset Pompe disease, with approvals and reimbursement expansion underway globally.
Clinical-stage and in-licensed assets where Amicus funds development/regulatory work and prepares for commercialization in targeted markets.
Products
Reported · share of revenue- Galafold82.3 %
- Pombiliti Opfolda17.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Amicus’s direct customers are typically specialty distributors and pharmacies that purchase Galafold® and Pombiliti® + Opfolda® and take control of product at delivery. Demand is driven by specialist physicians and treatment centers that diagnose and prescribe therapies for Fabry and Pompe disease, while access is heavily shaped by third-party payors and government reimbursement programs. Because these are rare diseases, patient identification, genetic testing (for Galafold amenability), and ongoing patient support are important to therapy uptake and persistence. Patient organizations and charitable foundations can influence awareness, access pathways, and affordability support, which makes compliant engagement a meaningful part of the commercial model.
Buy Galafold and Pombiliti + Opfolda for downstream dispensing; central to order flow and channel inventory dynamics.
Drive initiation and switching decisions based on efficacy, safety, convenience, and clinical guidelines for Fabry/Pompe.
Approve coverage, set reimbursement terms, and generate rebates/discounts that materially affect net product sales.
Influence diagnosis journeys, therapy selection, and affordability support; important for rare-disease adoption and persistence.
Strategy
Amicus is prioritizing growth of its two commercial franchises by expanding geographic reach, securing reimbursement, and deepening penetration in Fabry and Pompe patient populations. The company is also advancing next-generation therapies and novel technologies to extend its rare-disease platform beyond current products. Business development is a core lever, with management explicitly evaluating collaborations, in-licensing, and acquisitions to add marketed or late-stage assets aligned to rare and orphan diseases. The DMX-200 license illustrates a strategy of acquiring U.S. commercialization rights to a late-stage program while the partner continues to run the pivotal study, allowing Amicus to focus on regulatory submission and commercial build-out.
Rare-disease revenue growth depends on approvals, reimbursement, and patient identification across countries.
In-licensed or acquired assets can diversify beyond two products and extend growth runway in rare/orphan diseases.
Outsourced manufacturing and regulatory approvals can constrain supply and limit commercial execution if not de-risked.
Geography
Amicus commercializes Galafold® in over 40 countries, including the United States, European Union, United Kingdom, and Japan, reflecting a broad rare-disease footprint beyond a single market. Pombiliti® + Opfolda® is approved in the U.S., E.U., U.K., Canada, Australia, Switzerland, and Japan, with additional submissions and reimbursement processes ongoing. Manufacturing is largely outsourced to contract manufacturers under cGMP, creating operational dependence on external supply chains rather than company-owned plants. The company is working with WuXi on a second manufacturing facility for Pombiliti® in Dundalk, Ireland, which introduces regulatory-approval and execution considerations across jurisdictions.
Risks
Amicus’s revenue base is concentrated in two rare-disease products, so competitive entries, label changes, or reimbursement pressure can have an outsized impact on growth and pricing. The company relies on third-party manufacturers for active ingredients and finished goods, making it exposed to cGMP compliance, capacity constraints, and regulatory approval risk for new or expanded facilities (including the planned second Pombiliti site in Ireland). Commercial execution depends on distributors and pharmacies, and the company highlights risks around distributor performance, financial health, compliance, and potential disruption if agreements terminate. Like other biotech companies, Amicus faces ongoing regulatory, clinical-development, and cybersecurity risks, including vendor/supply-chain cyber incidents that could disrupt operations or trigger disclosure and reputational harm.
- Regulatory approval delays or failure for second Pombiliti facility (Dundalk, Ireland)Impact: HighLikelihood: Low
Although EMA approved, the facility may not be approved by FDA/other regulators, potentially delaying supply resilience and requiring additional capital.
Exposure: Manufacturing and regulatory execution; reliance on WuXi and facility readiness
- Distributor dependency and potential disruption of commercializationImpact: HighLikelihood: Low
Distributors may underinvest, face financial/compliance issues, or terminate/expire arrangements, interrupting sales and reducing revenue.
Exposure: Channel execution across geographies
- Cybersecurity incidents impacting Amicus or key vendors/manufacturersImpact: MediumLikelihood: Medium
Attacks could lead to data loss, ransomware costs, operational disruption, and reputational harm; supply-chain incidents can have similar effects.
Exposure: IT systems and third-party supply chain
- Failure to complete the pending transaction with BioMarinImpact: MediumLikelihood: Medium
Non-completion within expected timeframe or at all could adversely affect business, financial results, and operations.
Exposure: Corporate transaction execution
Accounting
Judgemental itemsNet product sales depend on estimates for rebates/discounts (government programs and payer terms) that can change with mix and regulations.
Impact: Affects reported net revenue, gross-to-net adjustments, and period comparability
Remeasurement of foreign-denominated balances can drive material swings in other income/expense as exchange rates move.
Impact: Introduces non-operating volatility that can obscure underlying operating trends
Similar listed companies
Publicly listed companies with a comparable business focus.
PTC Therapeutics, Inc
PTCT · Pharmaceutical Preparations
PTC Therapeutics is a U.S.-based global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders.
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
Catalyst Pharmaceuticals, Inc
Pharmaceutical Preparations
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026